Welcome to our dedicated page for HELIX BIOPHARMA news (Ticker: HBPCF), a resource for investors and traders seeking the latest updates and insights on HELIX BIOPHARMA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HELIX BIOPHARMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HELIX BIOPHARMA's position in the market.
Helix BioPharma Corp. announced the appointment of Artur Gabor as the new Chief Executive Officer and added three new members to its Board of Directors aimed at enhancing corporate governance and growth capabilities. The new board members include Jerzy Leszczyński, Christopher Maciejewski, and Jacek Antas, each bringing significant experience in their respective fields. This leadership change is expected to bolster the company's strategic direction in immuno-oncology therapies based on the proprietary DOS47 platform.
Helix BioPharma Corp. announced the resignation of Heman Chao as CEO and CSO, effective September 1, 2021. Chao, who joined in 2008, will transition to Chair of the Scientific Advisory Board. The Board appreciates his dedication to advancing immunotherapy research and will seek candidates for the new CEO. The company remains focused on its clinical programs, particularly the primary drug candidate L-DOS47, which is expected to drive future growth. The Board expresses confidence in the current management team.
Helix BioPharma Corp. announced the appointment of Marcum LLP as its new auditor, replacing BDO Canada LLP. A Notice of Change of Auditor has been filed under the company's SEDAR profile. Additionally, the company received conditional approval from the Toronto Stock Exchange to extend the exercise period of 4,830,175 common share purchase warrants for two years. These warrants represent approximately 3.4% of the company’s outstanding shares and were originally issued during private placements between July 2014 and August 2016.
Helix BioPharma Corp. has updated its progress on the divestiture of its remaining shares in Polish subsidiary Helix Immuno-Oncology S.A. The company accepted an offer from CAIAC Fund Management AG for gross proceeds of PLN6,700,000 (~CAD2,300,000). Due to COVID-19-related delays, the transaction's closing date has been extended to October 30, 2020, pending approval from the Financial Market Authority in Liechtenstein and a minimum capital raise of PLN7,300,000 by the fund.
FAQ
What is the market cap of HELIX BIOPHARMA (HBPCF)?
